Although several novel agents are on the horizon, including next-generation tyrosine kinase inhibitors for tertiary mutations ...
Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...
The treatment of head and neck squamous cell carcinoma (HNSCC) is set to undergo rapid changes, as molecular targeted therapy continues to make strides. HNSCCs are characterized by substantial ...
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines (ONC) is conducting a Phase 1a/1b ...
AUSTIN, Texas--(BUSINESS WIRE)--Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a ...
Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...
MedPage Today on MSN
Trop2 Drug Extends Survival in EGFR-Mutated Lung Cancer
The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...
Introduction Studies on human patellar and Achilles tendons have shown that tendon cells not only have the capacity to produce acetylcholine (ACh) but also express muscarinic ACh receptors (mAChRs), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback